HomeDiscoveryPipeline

Pipeline

Nerviano Medical Sciences' current portfolio includes anticancer compounds in clinical phase or in advanced stage of pre clinical development, in addition to research projects. Several projects are conducted within strategic alliances.

ENCORAFENIB
PRECLINICAL PHASE I PHASE II PHASE III
99% PHASE III
ENTRECTINIB
PRECLINICAL PHASE I PHASE II PHASE III
72% PHASE II
MILCICLIB
PRECLINICAL PHASE I PHASE II PHASE III
62% PHASE II
S81694
(NMS-P153, MPS1)
PRECLINICAL PHASE I PHASE II PHASE III
37% PHASE I
PCM-075
(NMS-P937, PLK1)
PRECLINICAL PHASE I PHASE II PHASE III
37% PHASE I
ADC-Payload (PNU-682)
PRECLINICAL PHASE I PHASE II PHASE III
12% PRECLINICAL
ADC-Payload (NMS-P945)
PRECLINICAL PHASE I PHASE II PHASE III
12% PRECLINICAL
Kinase inhibitor
program
PRECLINICAL PHASE I PHASE II PHASE III
12% PRECLINICAL
 
PRECLINICAL PHASE I PHASE II PHASE III
0% PRECLINICAL
DANUSERTIB (AURORA)
PRECLINICAL PHASE I PHASE II PHASE III
59% PHASE II
NMS-P088
(FLT3, KIT, CSF1R)
PRECLINICAL PHASE I PHASE II PHASE III
21% PRECLINICAL
NMS-P293
(PARP1)
PRECLINICAL PHASE I PHASE II PHASE III
18% PRECLINICAL
DISCOVERY programs
• PRE-PC
• LEAD OPTIMIZATION
• EARLY PROJECTS
PRECLINICAL PHASE I PHASE II PHASE III
12% PRECLINICAL
ADC-Payload
platform
PRECLINICAL PHASE I PHASE II PHASE III
12% PRECLINICAL